Plasma Fractionation Market By Product Type (Immunoglobulins {Intravenous Immunoglobulins, Subcutaneous Immunoglobulins, Other Immunoglobulins}, Coagulation Factor Concentrates {Factor VIII, Factor IX, Von Willebrand Factor, Prothrombin Complex Concentrate, Fibrinogen Concentrates, Factor XIII, Other Coagulation Factor Concentrates}, Albumin {Human albumin, Recombinant albumin} Protease Inhibitors, Others), By Method (Centrifugation, Depth Filtration, Chromatography, Others), By Application (Neurology, Immunology, Haematology, Critical care, Pulmonology, Hemato-Oncology, Rheumatology, Other .), By Distribution channel (Direct Sales, Distributors, Online sales), and By End-user (Hospitals and Clinics, Clinical Research Laboratories, Academic institutes, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Plasma Fractionation market accounted for USD 38.7 Billion in 2024 and is expected to reach USD 95.9 Billion by 2035, growing at a CAGR of around 8.6% between 2025 and 2035. The plasma fractionation market pertains to the industrial process of plasma purification for producing immunoglobulins, albumin, and coagulation factors for clinical application. Plasma-derived products are critical in managing many diseases such as immunodeficiencies, bleeding disorders, and critical illness. Growth is influenced by the rise in chronic and rare diseases, the development of sophisticated plasma processing techniques, and global plasma demand or plasma protein therapies.

Major players in the market pay more attention to the network of collecting plasma, raise the efficiency of fractionation, and conform to the mandatory requirements for the quality and security of plasma products. Also, growth factors such as the increasing demand for goods and services in emerging markets, together with the focus on higher quality, targeted treatment—personalized medicines—are favorable signs for the development of this industry.

Report Scope:

Market Dynamics

Rising prevalence of chronic and rare diseases requiring plasma-derived therapies.

One of the factors that support plasma fragment growth is the increasing incidence of chronic and rare diseases, which drives the market growth. Perennial conditions like hemophilia, primary immunodeficiency, and some neurological disorders necessarily mandate plasma-based therapeutic products like clotting factors and immunoglobulins. Given that more people are living longer, and more such diseases are being diagnosed, the need for these treatments will remain high. These diseases need plasma-derived products that have the potential to enhance the patient's standard of living.

Likewise, plasma fractions have garnered more opportunities in the market as there remains a possibility of upgrading plasma fractionation technologies to respond to the need for high-efficiency and lifesaving treatments. Moreover, the global population’s awareness of these therapies increases along with the improvements in the healthcare sector; more consumers try these treatments, helping expand this market even more. This combination and dependency on plasma-derived therapies thus offer enormous market prospects for companies within plasma fractionation.

Advancements in plasma fractionation technologies improving efficiency.

Newer technologies in plasma fractionation have improved the receptiveness and clearance procedures of plasma-derived products immensely. Technological advancements, including filtration and purification processes, have been developed and enhanced, enabling better plasma component separation with better yields in a shorter time. Technology too described a significantly important feature whereby plasmid automation of fractionation and purification facilities produces improved and constant results.

Thus, some examples of equipment technologies are harvesting and cleaning functions that use automation techniques instead of being done manually. They enhance both the quality and quantity of plasma-derived products while also assisting on the cost front, which makes the therapies available to a larger population of patients. The gradual advancement of these technologies is expected to fuel, in equal measure, future growth in the plasma fractionation market to meet the rising global need for plasma-derived therapies.

High production and processing costs of plasma-derived products.

The high levels of production and processing costs of plasma-derived products remain a major issue impacting the plasma Fractionation market. The processes of collection, separation, purification, and concentration of the plasma products through plasma fractionation are rather cumbersome and time-consuming, and they involve a good amount of cost. These costs are further magnified by the fact that most of the equipment in the process is specialty equipment, quality control, and manufacturing standards such as Good Manufacturing Practices (GMP).

First, there is a general scarcity of plasma, and secondly, due to the production of small quantities of therapies, the need for large volumes of plasma also drives up the costs. These financial constraints can limit market growth, particularly with the growth exponent of health care, as markets in developing nations may have small budgets to allocate. Besides, continuing volatility in raw material supply, with the constant need for investing to incorporate better technologies to produce safe food, also poses economic challenges to companies in the market.

Expansion of plasma collection centers in underpenetrated regions.

 The construction of these centers can enhance local health facilities, provide employment for people, and educate others about the role of plasma donations. They can improve relations with governments, NGOs, and healthcare organizations, which will allow global companies to reach many more consumers in the market and become stronger within the industry. The expansion of plasma-collecting facilities in underserved areas is one of the primary drivers of the plasma fractionation market's growth.

More plasma collecting and processing facilities would help meet the growing demand for raw plasma as the market for products produced from plasma grows, particularly in developing nations. The availability of crucial regimens is hampered by the extremely limited plasma-collecting systems in some parts of the world, particularly in Asia, Africa, and parts of Latin America. Companies may benefit from more collection centers since they can draw plasma from a larger patient base and contribute to a greater supply of plasma for fractionation.

Growing focus on personalized medicine using plasma-derived therapies.

The increasing use of biomolecular solutions for individualized diagnosis and treatment by plasma-based products is a major opportunity for the plasma fractionation market. Introducing the patient, the genetic and family backgrounds, and the characteristics of a definite disease, personalized medicine makes it possible to treat chronic and rare diseases, immunodeficiencies, and hemophilia. Immunoglobulins and clotting factors are derived from plasma and can be used to address every patient’s specific circumstance and thus optimize effectiveness and reduce side effects.

With the advancement of precision medicine into practice inside the healthcare systems, there is a strong trend for the derivation of plasma-based products that should be personalized for specific treatments. This trend fuels the need to come up with enhanced plasma fractionation technologies in a bid to produce intensified tailored therapies. Industry players who launch research on and production of such products should consider the new market opening by diversifying their products and targeting a customer base of a diverse body of patients.

Industry Experts Opinion

"Plasma fractionation is a vital process in the production of life-saving therapies for a wide range of conditions. The market for plasma fractionation continues to expand due to increasing demand for plasma-derived therapies, especially for immunodeficiencies and bleeding disorders."

• Dr. Robert Harris, Chief Scientific Officer at BioLife Plasma Services

Segment Analysis

Based on the product type, the plasma fractionation market has been classified into immunoglobulins and coagulation. Factor Concentrates, Albumin, Protease Inhibitors, and Other Plasma Products. The largest sector in the plasma fractionation industry is immunoglobulins, including "intravenous immunoglobulins (IVIG)" and "subcutaneous immunoglobulins (SCIG)." These therapies are used frequently as a treatment for immune disorders, autoimmune diseases, and other inflammatory processes.

IVIG is even more popular because it ensures immediate boosting of the immune system in patients with compromised immune systems. The need for immunoglobulins is likely to persist and grow even further in the future due to the constantly growing number of autoimmune diseases and primary immunodeficiencies all over the world. Furthermore, innovations in SCIG formulations have enabled the enhanced home administration of therapy, hence spurring market growth in this category. Immunoglobulins consequently mark a significant focus on facilitating a vast array of diseases, hence being the dominant product type in the plasma fractionation marketplace.

Based on the method type, the plasma fractionation market has been classified into centrifugation, depth filtration, chromatography, and others. The largest application area in the plasma fractionation market is centrifugation. This method is popular due to the high efficiency it has when it comes to the separation of plasma components due to their density. Centrifugation routinely involves the separation of immunoglobulins, clotting factors, and albumin plasma proteins, all of which are critical in therapy. The process is proven to be efficient. Easily reproducible and widely used in the first stages of plasma fractionation. Its affordability, ease of use, and high plasma throughput make it the most popular method in the market. In addition, research findings implemented in the aspect of centrifugation’s accuracy and effectiveness increase stand witness to the fact that it serves as the paramount technology that it is.

Regional Analysis

North America is anticipated to be the largest plasma fractionation better-quality market, primarily due to the enhanced healthcare industry, coupled with heightened plasma donation and key industry participants such as CSL Behring and Grifols. Plasma collection is highly developed in the USA, and it can be stated that the country plays an important role in plasma supply for fractionation and therapeutic use. The region enjoys an upsurge in the incidence of chronic and rare diseases that include hemophilia and primary immunodeficiencies, thus creating a market for plasma-derived products.

Smoothing government policies, strong research and development investment, and an increase in plasma processing technologies are giving further boosts to the market. Moreover, personalized medicine approaches and the usage of the latest fractionation technologies point out North America as the world’s key participant in the plasma fractionation market.

The Asia-Pacific Plasma Fractionation market is set for steady growth due to the rising number of people suffering from chronic diseases, higher population aging, and increasing healthcare consumption. Developing countries like China, India, and Japan are showing remarkable proactivity in the escalation of healthcare frameworks; therefore, improving the availability of plasma-derived treatments. The increasing network of plasma collection centers across the region and increasing awareness towards plasma donation also boost the market’s growth.

Government policies and collaborations with international stakeholders are driving innovation and the availability of better-quality plasma products. On the same note, the Asia-Pacific region is also replete with untapped markets and relatively cheap manufacturing potential for plasma fractionation operators around the world. The need for new therapeutic solutions coupled with the progressive development of healthcare systems across the region implies that the region has a large potential in the sphere of the plasma fractionation market.

Competitive Landscape

These companies that control the plasma fractionation market today are CSL Behring, Grifols S.A., Takeda Pharmaceutical Company, Octapharma, Kedrion Biopharma, and Biotest AG. These companies have a strong position in the market thanks to the fact that they supply plasma-derived products such as immunoglobulins, albumin, and coagulation factor concentrates. They are keen on increasing their product offering through regular capital investment in research on advancing plasma fractionation techniques with particular regard to efficiency and accuracy. The three major forms of alliances to enhance market positioning and plasma supply chains are mergers and acquisitions, as well as strategic partnerships.

Furthermore, the major players are signing partnerships with emerging markets for a higher collection network of plasmas and constant availability of raw materials. Other factors are alternatively driving the competition in the market, such as technologies used in chromatography and centrifugation to enhance operational capacity in these value-added firms. As plasma-derived products receive increasing global attention, these firms are improving production capacities, exploring new markets, and enhancing the quality of these products to address the increasing patient-demanding population.

Plasma Fractionation Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In September 2024, Kedrion Biopharma expanded its operations in Latin America by launching new plasma collection centers, aiming to enhance its global supply of critical biopharmaceutical products.
• In August 2024, Octapharma opened a state-of-the-art manufacturing facility in North America to strengthen its production capabilities, aiming to meet the rising demand for its plasma-derived therapies.

Report Coverage:

By Product Type

• Immunoglobulins
  • Intravenous Immunoglobulins
  • Subcutaneous Immunoglobulins
  • Other Immunoglobulins
• Coagulation Factor Concentrates
  • Factor VIII
  • Factor IX
  • Von Willebrand Factor
  • Prothrombin Complex Concentrate
  • Fibrinogen Concentrates
  • Factor XIII
  • Other Coagulation Factor Concentrates
• Albumin
  • Human albumin
  • Recombinant albumin
• Protease Inhibitors
• Others

By Method

• Centrifugation
• Depth Filtration
• Chromatography
• Others

By Application

• Neurology
• Immunology
• Haematology
• Critical care
• Pulmonology
• Hemato-Oncology
• Rheumatology
• Other

By Distribution channel

• Direct sales
• Distributors
• Online sales

By End-user

• Hospitals and Clinics
• Clinical Research Laboratories
• Academic institutes
• Others

By Region

North America

• U.S.
• CanThe ada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• CSL Behring
• Takeda Pharmaceutical Company Limited
• Grifols, S.A.
• Octapharma AG
• Kedrion S.p.A.
• LFB S.A.
• Biotest AG
• Sanquin
• Bio Products Laboratory Ltd.
• China Biologic Products Holdings Inc.
• GC Pharma
• Hualan Bioengineering Co., Ltd.
• Japan Blood Products Organization
• Shanghai RAAS Blood Products Co., Ltd.
• Emergent BioSolutions
• Intas Pharmaceuticals Ltd.

Frequently Asked Questions (FAQs)